Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

154
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
154
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

657
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
657
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

164
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
164
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

226
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
226
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

342
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
342

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Comparing Methods to Assess Treatment Effect Heterogeneity in General Parametric Regression Models.

Statistics in medicine·2026
Same author

Overview and Practical Recommendations on Using Shapley Values for Identifying Predictive Biomarkers via CATE Modeling.

Statistics in medicine·2026
Same author

Evaluating Causal Effects on Time-to-Event Outcomes in an RCT in Oncology With Treatment Discontinuation.

Biometrical journal. Biometrische Zeitschrift·2025
Same author

Futility Analyses for the MCP-Mod Methodology Based on Longitudinal Models.

Statistics in medicine·2025
Same author

Randomization-Based Inference for MCP-Mod.

Statistics in medicine·2025
Same author

Closed MCP-Mod for Pairwise Comparisons of Several Doses With a Control.

Statistics in medicine·2025
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same journal

Beyond Fixed Thresholds: Optimizing Summaries of Wearable Device Data via Piecewise Linearization of Quantile Functions.

Statistics in medicine·2026
Same journal

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Statistics in medicine·2026
Same journal

Causal Effects on Nonterminal Event Time With Application to Antibiotic Usage and Future Resistance.

Statistics in medicine·2026
查看所有相关文章

相关实验视频

Updated: Jan 10, 2026

Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

2.1K

使用个性化治疗效果来评估治疗效果异质性

Konstantinos Sechidis1, Cong Zhang2, Sophie Sun3

  • 1Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland.

Statistics in medicine
|November 27, 2025
PubMed
概括
此摘要是机器生成的。

这项研究引入了新的方法来评估临床试验中的治疗效果异质性 (TEH). 这些方法有助于通过了解治疗方法如何影响个体患者来个性化医疗.

关键词:
有条件的平均治疗效果.不同质的治疗效果.机器学习是机器学习.这些都是meta-learners.小组分析小组分析

更多相关视频

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.1K

相关实验视频

Last Updated: Jan 10, 2026

Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

2.1K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.1K

科学领域:

  • 临床试验方法论 临床试验方法论
  • 生物统计学 生物统计学
  • 药物监督 药物监督 药物监督

背景情况:

  • 评估治疗效果异质性 (TEH) 对药物开发和个性化医学至关重要.
  • 了解患者对治疗反应的变化,可以为临床决策提供信息.
  • 现有的方法可能无法完全捕捉个性化治疗效果.

研究的目的:

  • 引入基于个性化治疗效应的新方法来评估治疗效应异质性 (TEH).
  • 开发用于全球异质性测试,共变效应修改排名和个性化治疗效应估计的工具.
  • 将这些方法整合到一个强大的临床试验分析框架中.

主要方法:

  • 使用双重强大的 (DR) 学习器推断反映因果对比的伪结果.
  • 将伪结果应用于全球异质性测试,共变效应修改分析和个性化治疗效应估计.
  • 将DR-learner与模拟中的替代方法进行了比较,并对牛皮关节炎 (PsA) 试验进行了聚合分析.

主要成果:

  • 在估计个性化治疗效果和评估异质性方面,DR学习者表现强.
  • 与竞争方法相比,模拟研究验证了拟议方法的有效性.
  • 对牛皮关节炎 (PsA) 试验的分析揭示了对治疗效果异质性的重大见解.

结论:

  • 基于DR学习者的新方法为评估治疗效应异质性 (TEH) 提供了强大的框架.
  • 这些方法增强了药物开发中的决策,并促进了个性化医疗战略.
  • 与WATCH工作流的集成为临床试验赞助商提供了全面的TEH分析.